The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients.
Alkaline phosphatase (AP) is the classic marker of bone formation, especially in cancer patients, but the interpretation of its measurement is complicated by the existence of various circulating isoenzymes, especially of liver origin. The introduction of a mass measurement of the bone isoenzyme of AP (BAP) by an immunoradiometric assay has markedly improved the sensitivity and the specificity of the determination. We measured BAP and other markers of bone turnover in 46 patients with tumour-induced hypercalcaemia (TIH), which is an interesting model for evaluating markers of bone formation because of the uncoupling between bone formation and bone resorption found by histomorphometric techniques. The extent of bone metastatic involvement was evaluated by planimetry on bone scintigraphy. Mean (+/- S.D.) BAP concentrations were slightly higher in patients with TIH than in healthy subjects, 15.5 +/- 8.5 versus 12.4 +/- 3.5 micrograms/L (P < 0.05). However, the scatter of the data in TIH patients was quite marked. Increased values (10/46 patients, 22%) occurred only in patients with bone metastases. Total AP, gamma GT and BGP levels, as well as markers of bone resorption, were not significantly different between patients with or without bone metastases. BAP levels were significantly correlated with AP (rs = 0.63; P < 0.01) but not with BGP levels nor with markers of bone resorption. BAP levels were also correlated with the extent of bone uptake at scintigraphy (rs = 0.54; P < 0.01), but this was not the case for total AP or BGP. In the 36 patients re-evaluated when normocalcemic after pamidronate therapy, BAP levels increased from 16.3 +/- 9.2 to 22.2 +/- 21.3 micrograms/L (P < 0.05) but there were no significant changes in AP or BGP concentrations. In summary, our data confirm the existence of an uncoupling in bone turnover in TIH and indicate that cancer hypercalcaemia is another pathological condition characterised by a discordance between BAP and BGP concentrations. BAP levels appear to be a better reflection of bone metastatic involvement than total AP or BGP and their short-term increase after pamidronate therapy could reflect the recently described effects of bisphosphonates on osteoblasts.
Body
J J
JJ
Bone Metabolism Unit, Service de Médecine et Laboratoire d'Investigation Clinique et d'Oncologi Expérimentale, Liège, Belgium.
Dumon
J C
JC
Blocklet
D
D
Darte
C
C
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000201:enzymology / Q000556:secondary; D001862:Bone Resorption / Q000201:enzymology; D001842:Bone and Bones / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology; D015592:Immunoradiometric Assay; D007527:Isoenzymes / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000502:physiology; D010257:Paraneoplastic Syndromes / Q000201:enzymology*
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D000469:Alkaline Phosphatase